The IPSET survival model derives from multivariate analysis of 867 patients diagnosed with essential thrombocythemia (ET) by WHO criteria. The model was validated in two independent cohorts including 132 WHO-defined ET and 234 Polycythemia vera Study-Group-defined ET patients.
|Risk variables||HR, Ci 95%||Score 0||Score 1||Score 2|
|Age [years]||6.5, 3.9–10.7||< 60||> 60|
|Leukocyte count [G/L]||3.1, 2–4.7||< 11||> 11|
|Thrombosis history||2.9, 1.9–4.5||no||yes|
|Score||Risk category||Median survival|
|1–2||Intermediate risk||17.5–24.5 years|
|3–4||High risk||7.1–14.7 years|
Passamonti F et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.. Blood 2012; 120 (6):1197-1201.